Verix boosts life science AI capabilities with start-up.ai acquisition
Summary
The deal enables Verix to further improve its capacities to use AI to advance the brand growth of life science companies. Pharmaceutical firms usually depend upon consulting analytical services for marketing and sales decisions related to their strategy and execution. Verix states that it leverages AI to provide more in-depth, precise data on the market more quickly and at a lower cost. Verix CEO Doron Aspitz stated: “In our time working with start-up.ai, we were consistently impressed with their AI capabilities and innovative approach to solving customer challenges. “Adding the start-up.ai team to Verix was a natural decision for us and we are excited about what our new capabilities will enable us to deliver to our customers and partners around the world.”